JP2023512084A5 - - Google Patents

Info

Publication number
JP2023512084A5
JP2023512084A5 JP2022546426A JP2022546426A JP2023512084A5 JP 2023512084 A5 JP2023512084 A5 JP 2023512084A5 JP 2022546426 A JP2022546426 A JP 2022546426A JP 2022546426 A JP2022546426 A JP 2022546426A JP 2023512084 A5 JP2023512084 A5 JP 2023512084A5
Authority
JP
Japan
Prior art keywords
antibody
composition according
subject
drug conjugate
months
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022546426A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023512084A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/015685 external-priority patent/WO2021155129A1/en
Publication of JP2023512084A publication Critical patent/JP2023512084A/ja
Publication of JP2023512084A5 publication Critical patent/JP2023512084A5/ja
Pending legal-status Critical Current

Links

JP2022546426A 2020-01-31 2021-01-29 抗cd30抗体薬物コンジュゲート及び非ホジキンリンパ腫の治療のためのその使用 Pending JP2023512084A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062968808P 2020-01-31 2020-01-31
US62/968,808 2020-01-31
PCT/US2021/015685 WO2021155129A1 (en) 2020-01-31 2021-01-29 Anti-cd30 antibody-drug conjugates and their use for the treatment of non-hodgkin lymphoma

Publications (2)

Publication Number Publication Date
JP2023512084A JP2023512084A (ja) 2023-03-23
JP2023512084A5 true JP2023512084A5 (cg-RX-API-DMAC7.html) 2024-02-02

Family

ID=74672470

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022546426A Pending JP2023512084A (ja) 2020-01-31 2021-01-29 抗cd30抗体薬物コンジュゲート及び非ホジキンリンパ腫の治療のためのその使用

Country Status (10)

Country Link
US (1) US20230090868A1 (cg-RX-API-DMAC7.html)
EP (1) EP4096713A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023512084A (cg-RX-API-DMAC7.html)
KR (1) KR20220146488A (cg-RX-API-DMAC7.html)
CN (1) CN115697400A (cg-RX-API-DMAC7.html)
AU (1) AU2021212193A1 (cg-RX-API-DMAC7.html)
CA (1) CA3169661A1 (cg-RX-API-DMAC7.html)
IL (1) IL295202A (cg-RX-API-DMAC7.html)
MX (1) MX2022009389A (cg-RX-API-DMAC7.html)
WO (1) WO2021155129A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120826242A (zh) * 2023-03-09 2025-10-21 浙江特瑞思药业股份有限公司 抗cd20抗体药物偶联物在制备治疗套细胞淋巴瘤的药物中的用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4714681A (en) 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4925648A (en) 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
EP0739904A1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
DK0553244T4 (da) 1990-10-05 2005-08-01 Celldex Therapeutics Inc Målrettet immunostimulering med bispecifikke reagenser
AU8727291A (en) 1990-10-29 1992-06-11 Cetus Oncology Corporation Bispecific antibodies, method of production, and uses thereof
EP0582595A1 (en) 1991-04-26 1994-02-16 Surface Active Limited Novel antibodies, and methods for their use
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
EP1306095A3 (en) 1992-03-05 2003-06-25 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
ATE139900T1 (de) 1992-11-13 1996-07-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
PT1974747E (pt) * 1998-08-11 2012-09-05 Biogen Idec Inc Terapias de combinação para linfomas de células b compreendendo a administração de anticorpo anti-cd20
US7090843B1 (en) 2000-11-28 2006-08-15 Seattle Genetics, Inc. Recombinant anti-CD30 antibodies and uses thereof
KR101641345B1 (ko) * 2007-10-12 2016-07-20 시애틀 지네틱스, 인크. 항체-약물 접합체를 이용한 병용 요법
WO2010081004A1 (en) 2009-01-09 2010-07-15 Seattle Genetics, Inc. Weekly dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates
KR20210090298A (ko) * 2012-10-30 2021-07-19 에스퍼란스 파마슈티컬스, 인코포레이티드 항체/약물 컨쥬게이트 및 이의 사용 방법
EP3404024B1 (en) * 2016-01-14 2020-11-18 Kangpu Biopharmaceuticals, Ltd. Quinazolinone derivative, preparation method therefor, pharmaceutical composition, and applications
SG11201808625QA (en) * 2016-04-04 2018-10-30 Chemocentryx Inc SOLUBLE C5aR ANTAGONISTS
SG11201908520TA (en) * 2017-03-14 2019-10-30 Shimadzu Corp Method for simultaneous quantification of monoclonal antibodies
EP3744719B1 (en) * 2018-01-25 2023-06-07 Fujimoto Co., Ltd. Thiophene derivative and use thereof
EP3752190B1 (en) * 2018-02-12 2022-07-06 Forty Seven, Inc. Anti-cancer regimen using anti-cd47 and anti-cd20 antibodies

Similar Documents

Publication Publication Date Title
KR102923588B1 (ko) 항 bcma 항체 및 감마 세크레타제 억제제의 조합 요법
JP5823874B2 (ja) 抗CD30vc−PAB−MMAE抗体−薬物コンジュゲートのウィークリー投与計画
JP2011507932A5 (cg-RX-API-DMAC7.html)
JP2021518394A5 (cg-RX-API-DMAC7.html)
US20240307541A1 (en) Methods for local and systemic treatment of cancers, tumors and tumor cells
RU2010130977A (ru) Иммуноконъюгаты, направленные на cd138, и их применение
IL274122B1 (en) Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer
JP2022513386A5 (cg-RX-API-DMAC7.html)
JP2021501776A5 (cg-RX-API-DMAC7.html)
JP2023508496A5 (cg-RX-API-DMAC7.html)
JP2021523233A5 (cg-RX-API-DMAC7.html)
JP2015500822A5 (cg-RX-API-DMAC7.html)
JP2021523158A5 (cg-RX-API-DMAC7.html)
US20220313822A1 (en) Near-infrared (nir) photoimmunotherapy (pit) for the treatment of cancers using anti-cd25 antibody-phthalocyanine dye conjugate and anti-pd1 antibody
HK1213782A1 (zh) 在诊断和治疗类风湿性关节炎中使用的包含抗-cd6单克隆抗体的药物组合物
JP2022541591A5 (cg-RX-API-DMAC7.html)
JP2021534165A5 (cg-RX-API-DMAC7.html)
JP2023500697A5 (cg-RX-API-DMAC7.html)
JP2025501978A5 (cg-RX-API-DMAC7.html)
JP2023500888A5 (cg-RX-API-DMAC7.html)
JP2026001086A (ja) 抗cd30抗体薬物複合体療法の副作用を軽減する方法
US20230190949A1 (en) Methods of treating cancer using a combination of anti-cd30 antibody-drug conjugates
JP2022502508A5 (cg-RX-API-DMAC7.html)
JP2021501800A5 (cg-RX-API-DMAC7.html)
TW202207976A (zh) 使用免疫檢查點抑制劑抗體治療癌症之方法和組合